Servier India Launches Biomarker Testing Initiative for Cancer Diagnosis

 



Servier India, the subsidiary of the French pharmaceutical group Servier, has entered into a strategic partnership with two genomic laboratories, MedGenome and Strand Life Sciences, to improve access to molecular testing for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) across India. This collaboration aims to make precision oncology more accessible by offering advanced biomarker testing at subsidised rates.

Expanding Access to Molecular Testing

The new initiative seeks to bridge the gap in access to quality molecular diagnostics, which are typically available only in urban centres. Through this programme, Servier India will offer a customised biomarker testing panel for AML and CCA, helping clinicians identify key mutations such as IDH1 and IDH2. Importantly, these specific mutation tests will be provided free of cost to patients in the government healthcare sector, promoting equity in cancer care access.

Focus on Precision Oncology

According to Servier India’s management, the availability of timely molecular testing can significantly improve treatment decisions and patient outcomes. Early genetic analysis allows oncologists to tailor therapies based on the molecular profile of each patient’s cancer, leading to improved prognosis and survival rates. The initiative underscores Servier’s commitment to advancing precision medicine and integrating genetic testing into routine oncology practice.

Collaborative Approach for Last-Mile Delivery

Servier India highlighted that the success of this programme relies on seamless collaboration among laboratories, clinicians, and patient networks. By working closely with MedGenome and Strand Life Sciences, the company aims to strengthen diagnostic infrastructure and reduce the delays that often occur between diagnosis and treatment initiation. This effort represents a model of coordinated healthcare delivery focused on timely cancer management.

Holistic Patient Support Through ‘Servier Care’

The biomarker testing drive forms part of the ‘Servier Care’ patient support initiative, which provides eligible cancer patients with comprehensive care including financial assistance, drug support, and subsidised diagnostics. The programme reinforces Servier’s mission to make innovative therapies and diagnostics more accessible, especially for patients in underserved regions of India.

#CancerResearch
#FightCancer
#CancerAwareness
#Oncology
#CancerSurvivor
#EndCancer
#CancerPrevention
#CancerBiology
#CureCancer
#CancerSupport

World Cell Biologist Awards: 

Website Link : cellbiologist.org 

Follow Us On : 
Tumblr ; tumblr.ccom/

Comments

Post a Comment

Popular posts from this blog

Uttrakhand Forest Department Establishes Mahabharata Vatika

Image
  The Uttarakhand Forest Department has established two gardens in Haldwani, showcasing plant species referenced in ancient Indian epics. These gardens, named Ramayana Vatika and Mahabharata Vatika, aim to highlight the ecological wisdom embedded in these texts. Mahabharata Vatika Overview Mahabharata Vatika spans one acre and features 37 plant species mentioned in the epic. Chief Conservator of Forests Sanjeev Chaturvedi emphasised the research behind selecting these species. The garden features important plant species such as: Ecological Significance The garden puts stress on the importance of forests as depicted in the Mahabharata. It references the Vana Parva, which discusses tree planting and wildlife conservation . The epic highlights the mutual dependence of tigers and forests, a concept vital to contemporary conservation efforts. Cultural Connections Chaturvedi brought into light that the Mahabharata teaches the spiritual significance of planting trees. He mentioned Bhish...
Read more

What is Zolgensma?

Image
  Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscle function. In India, treatment options are limited, mainly due to high costs. The gene therapy drug, Zolgensma , costs around 16 crore rupees. Despite this, some families are finding ways to access treatment. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that leads to the loss of motor neurons in the spinal cord. This results in muscle weakness and atrophy. Symptoms often appear in infancy. Children may struggle with basic movements like lifting their heads or crawling. Early diagnosis is crucial for effective treatment. About Zolgensma Zolgensma (onasemnogene abeparvovec-xioi) is a revolutionary gene therapy for SMA. It addresses the root cause by replacing the missing or defective SMN1 gene . This therapy can improve motor function in affected children. Although it is costly, it represents hope for many families. SMA is not as rare as once thought. The global prevalence is estimated at 1 in ...
Read more

CAR T-Cell Therapy for Cancer

Image
  India has recently made strides in cancer treatment with the introduction of CAR T-cell therapy . The results from the first clinical trials have been published in The Lancet, showcasing a remarkable success rate. This therapy is a game changer for patients with blood cancers. It offers hope to those who have exhausted other treatment options. What is CAR T-Cell Therapy? CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative treatment that harnesses the body’s immune system. It trains T-cells to target and destroy cancer cells. This therapy is specifically designed for certain blood cancers. It is particularly beneficial for patients whose cancer has relapsed or failed to respond to standard treatments. Clinical Trial The clinical trials reported a response rate of nearly 73%. This indicates that number of patients benefited from the treatment. The trials also provided critical data on survival rates for patients with acute lymphoblastic leukaemia and l...
Read more